Speciality Medicines passes all resolutions at fifth annual general meeting
- All resolutions at Speciality Medicines' 5th AGM passed with 100% votes in favor
- Total votes polled stood at 5,534,760 with zero votes against or invalid
- Promoter group voted 99.08% of held shares, while public non-institutions voted 35.29%
- Meeting held virtually on September 28, 2026, with 13 shareholders attending via video conferencing
*this image is generated using AI for illustrative purposes only.
Speciality Medicines Limited concluded its 5th Annual General Meeting (AGM) on September 28, 2026, with shareholders unanimously approving all proposed resolutions. The meeting, conducted via video conferencing, saw a total of 5,534,760 votes polled in favor of both agenda items, with zero votes cast against.
The primary resolutions involved the adoption of audited financial statements for the fiscal year ended March 31, 2026, and the re-appointment of Sumit Goyani as Whole-Time Director. The company reported that no invalid votes were recorded during the remote e-voting process managed by National Securities Depository Limited (NSDL).
Voting participation and turnout
The AGM was held virtually via the ZOOM platform, with the registered office serving as the deemed venue. Out of 410 shareholders on the record date of September 21, 2026, 13 participants attended the meeting through video conferencing. This included five from the promoter group and eight from the public category. No physical attendance was recorded as per MCA circulars permitting virtual meetings.
Remote e-voting commenced on September 25, 2026, and closed on September 27, 2026. During the meeting itself, an additional facility for remote electronic voting was available for attendees who had not previously voted.
Resolution outcomes
Both ordinary resolutions were passed with 100% support from the votes polled. The detailed breakdown of voting results is presented below:
| Resolution | Description | Votes In Favour | Votes Against | Result |
|---|---|---|---|---|
| 1 | Adoption of audited financial statements for FY26 | 5,534,760 | 0 | Passed |
| 2 | Re-appointment of Sumit Goyani (DIN: 07885780) | 5,534,760 | 0 | Passed |
The scrutinizer’s report confirmed that the promoter group held 3,815,500 shares, while public non-institutional shareholders held 4,970,296 shares. Public institutional shareholders held no shares eligible for voting in this instance.
What the numbers show
A significant concentration of voting power was evident in the promoter group, which held approximately 43.4% of the total shares held by voting categories (3,815,500 out of 8,785,796 total shares considered). However, the actual turnout among public non-institutional shareholders was notably lower compared to the promoters. While promoters voted 99.08% of their held shares, public non-institutional shareholders voted only 35.29% of their holdings. This disparity highlights a strong alignment within the promoter group but relatively passive engagement from the broader retail shareholder base regarding routine governance matters like financial statement adoption.
Historical Stock Returns for Speciality Medicines
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.66% | +9.93% | +6.35% | +30.98% | +30.98% | +30.98% |
How will the unanimous re-appointment of Sumit Goyani influence Speciality Medicines Limited's strategic direction and operational stability in the coming fiscal year?
What specific growth initiatives or capital expenditure plans are outlined in the newly adopted FY26 financial statements that could impact future profitability?
Given the low public shareholder turnout, what measures might the company implement to improve retail investor engagement and governance transparency in future AGMs?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
